CancerVAX, Inc. is a pre-clinical biotechnology company developing immunotherapy cancer treatments that use the body’s immune system to fight cancer.
By leveraging cutting-edge CRISPR and mRNA technologies, we are on a quest to develop a breakthrough Universal Cancer Vaccine. Much like the COVID-19 vaccines that train the body to recognize and destroy the coronavirus, we are developing cancer vaccines that train the body to target and destroy cancer cells.
As we search for a universal cancer vaccine, we are also developing conventional immunotherapy treatments. Our initial program, performed at the UCLA Jonsson Comprehensive Cancer Center, is targeted at treating Ewing Sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults. There is currently no FDA approved treatment to prevent recurrence.
We intend to become a dominate player in the immunotherapy space by partnering with leading researchers and institutions to develop a robust portfolio of cancer vaccines. We look forward to the day when treating cancer will be as simple as getting a flu shot.